EU CHMP Opinions and MAA Updates
Executive Summary
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
You may also be interested in...
Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.
Gilead Goes Full Steam Ahead In Oncology With Big Lung Cancer Push
The company has eight lung cancer trials running and plans for nine by the end of the year, including five with Trodelvy alone. Gilead is also looking ahead to an FDA verdict on lenacapavir.
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.